SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third
quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a
conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: |
|
|
|
Thursday, November 3, 2016 |
| Time: |
|
|
|
4:30 p.m. ET |
| Dial-in numbers: |
|
|
|
+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: |
|
|
|
1738305 |
| Live webcast: |
|
|
|
www.retrophin.com in the "Events & Presentations"
section of the "Investors" page
|
| |
|
|
|
|
A replay of the call will be available from 7:30 p.m. ET, November 3, 2016 to 11:59 p.m. ET, November 10, 2016.
The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 1738305.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to
people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring
clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental
glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease,
and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically
begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway.
Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®,
Cholbam® and Chenodal®.
Retrophin.com
Contact: (Investors) Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
